Doxy-PEP Explained: How to Get STI Prevention Prescribed Online — and the Antibiotic-Resistance Debate
Doxy-PEP (doxycycline post-exposure prophylaxis) is a strategy where you take a single 200 mg dose of doxycycline within 72 hours after unprotected sex to reduce your risk of bacterial STIs—specifically chlamydia, syphilis, and gonorrhea. Clinical trials show it cuts chlamydia and syphilis infections by more than 70%, and a growing number of telehealth providers can now prescribe it without an in-person visit. The approach is backed by CDC guidelines published in 2024, but it comes with important caveats around gonorrhea resistance that every prospective user should understand before starting.
What is doxy-PEP and how does it work?
Doxycycline is a broad-spectrum tetracycline antibiotic used for decades to treat chlamydia, acne, tick-borne illness, and respiratory infections. When used as post-exposure prophylaxis, a single 200 mg dose taken within 72 hours of a sexual exposure creates antibiotic levels in the body sufficient to suppress or eliminate small bacterial inocula before they establish a full-blown infection.
Three large randomized controlled trials—including the landmark DoxyPEP trial published in the New England Journal of Medicine in 2023—established the evidence base for CDC recommendations. In those trials, participants who took doxycycline within 72 hours of condomless sex saw:
- More than 70% reduction in chlamydia infections
- More than 70% reduction in syphilis infections
- Approximately 50% reduction in gonorrhea infections (in initial trial conditions)
The CDC formalized these findings into clinical guidelines published in June 2024, recommending doxy-PEP for a defined population as an additional layer of protection—not a replacement for condoms, regular STI screening, or HIV PrEP.
Who qualifies for doxy-PEP according to CDC guidelines?
The CDC 2024 guidelines recommend that providers offer doxy-PEP, following shared decision-making, to:
- Gay, bisexual, and other men who have sex with men (MSM) who have had a diagnosed bacterial STI—chlamydia, syphilis, or gonorrhea—in the past 12 months
- Transgender women (TGW) meeting the same 12-month STI history criterion
Providers may also discuss doxy-PEP with MSM and transgender women who have not had a recent STI but who engage in sexual activities that carry elevated ongoing exposure risk.
The CDC currently makes no recommendation for cisgender women, cisgender heterosexual men, transgender men, or other queer and nonbinary persons—not because doxy-PEP is considered unsafe in these groups, but because clinical trial data is insufficient to establish a clear benefit-risk profile. Research in these populations is ongoing.
| Population | CDC Recommendation |
|---|---|
| MSM with bacterial STI in past 12 months | Offer doxy-PEP (recommended) |
| Transgender women with bacterial STI in past 12 months | Offer doxy-PEP (recommended) |
| MSM/TGW without recent STI but at ongoing risk | Discuss doxy-PEP (shared decision-making) |
| Cisgender women | No recommendation (insufficient trial data) |
| Cisgender heterosexual men | No recommendation (insufficient trial data) |
| Transgender men, nonbinary persons | No recommendation (insufficient trial data) |
How do I get doxy-PEP prescribed? Can I get it online?
Yes — licensed telehealth providers can prescribe doxy-PEP after a secure video or asynchronous consultation. A typical appointment covers your sexual health history, recent STI and HIV testing results, allergy history, and any medications that might interact with doxycycline. Most visits take 15–20 minutes.
The general process:
- Book a telehealth appointment with a licensed provider familiar with sexual health — your primary care doctor, a sexual-health-focused telehealth platform, or Omnia TeleHealth’s STI/STD Testing & Treatment service
- Discuss your eligibility — the provider reviews your sexual health history and recent STI testing
- Receive the prescription — doxycycline 200 mg sent electronically to your pharmacy
- Take 200 mg within 72 hours of condomless sexual exposure; do not exceed 200 mg per 24-hour period
- Return for monitoring — the CDC recommends baseline and follow-up STI testing at all sites of exposure every 3–6 months
Doxycycline is a generic medication. A supply of 100 mg tablets (two = one 200 mg dose) typically costs $4–$10 at major pharmacies. The telehealth consultation is the main variable cost. All-in monthly costs for regular doxy-PEP users typically range from $30 to $60, depending on how often you use a dose and which platform you consult.
What is the antibiotic-resistance concern with doxy-PEP?
This is the most important conversation to have with your provider before starting, and the CDC guidelines are transparent about the uncertainty.
The gonorrhea problem. Initial RCT data showed roughly 50% reduction in gonorrhea infections. But 2026 real-world observational data from Southern California painted a more complicated picture. Among patients using doxy-PEP from January 2023 through mid-2025, published data showed that effectiveness against gonorrhea fell from approximately 42% in early 2023 to near zero by the end of the study period—meaning the intervention appeared to offer no protective benefit against gonorrhea after roughly two years of community-level use.
The underlying mechanism: Neisseria gonorrhoeae has a well-documented capacity for rapid resistance development. The proportion of gonorrhea isolates carrying the tetM resistance gene rose from under 10% in 2020 to more than 30% by early 2024. As resistant strains spread through sexual networks where doxy-PEP is widely used, the antibiotic becomes progressively less effective against this particular pathogen.
The chlamydia and syphilis picture remains meaningful. By contrast, real-world effectiveness against chlamydia (~66%) and syphilis (~61%) has remained clinically significant, if slightly below trial conditions. Treponema pallidum (syphilis) and Chlamydia trachomatis develop tetracycline resistance far more slowly than gonorrhea, making doxy-PEP a more durable prevention tool for these two infections.
Broader resistance and microbiome concerns. Regular doxycycline use also raises questions about changes to the gut and genital microbiome and potential for resistance transfer to commensal organisms. The CDC acknowledges that additional research is needed to fully characterize these long-term risks.
| STI | Doxy-PEP Effectiveness (Trials) | Real-World Effectiveness (2026 data) | Resistance Trend |
|---|---|---|---|
| Chlamydia | ~76% reduction | ~66% | Stable; tetracycline resistance low |
| Syphilis | ~78% reduction | ~61% | Stable; slow resistance development |
| Gonorrhea | ~50% reduction (early) | ~0% (by late 2025 in some regions) | Rapidly increasing tetracycline resistance |
What monitoring is required if I use doxy-PEP?
The CDC recommends that anyone prescribed doxy-PEP return for comprehensive STI screening every 3–6 months. At each visit, a provider should:
- Screen for chlamydia, gonorrhea, and syphilis at all relevant anatomic sites of exposure (oropharyngeal, rectal, urogenital)
- Reassess ongoing need and current risk level
- Review HIV status and PrEP use
- Monitor for antibiotic-related side effects—GI upset is the most common; take doxycycline with food and a full glass of water, and avoid lying down for at least 30 minutes after the dose
Because gonorrhea resistance data is rapidly evolving, some providers recommend culture-based gonorrhea testing at follow-up visits to detect any resistant infections early.
Is doxy-PEP the same as PrEP?
No — both are biomedical prevention strategies, but they target entirely different pathogens and use different timing. Here’s how they compare:
| Feature | PrEP (HIV pre-exposure prophylaxis) | Doxy-PEP (bacterial STI post-exposure prophylaxis) |
|---|---|---|
| Target pathogen | HIV | Chlamydia, syphilis, gonorrhea (bacterial STIs) |
| Timing | Daily (or on-demand 2-1-1 for eligible regimens) | Within 72 hours after sex — event-driven |
| Medications | Tenofovir/emtricitabine; cabotegravir LA injection | Doxycycline 200 mg |
| CDC target population | Anyone at substantial HIV risk | MSM and TGW with recent bacterial STI |
| Effect on the other | None | No effect on HIV |
Many people who take PrEP for HIV prevention are also candidates for doxy-PEP. The two interventions are often co-prescribed to address the full spectrum of STI risk in high-exposure individuals.
Does doxy-PEP interact with birth control or other medications?
Before starting doxy-PEP, disclose your full medication list to the prescribing provider. Key interactions include:
- Hormonal birth control: Traditional guidance suggests backup contraception during a course of doxycycline; evidence on clinically significant interaction is mixed but the caution is standard practice
- Blood thinners (warfarin): Doxycycline can enhance anticoagulant effects; monitoring may be warranted
- Antacids, calcium supplements, or dairy taken simultaneously: Chelation can significantly reduce doxycycline absorption — take at least 2 hours apart
- Sun sensitivity: Doxycycline increases photosensitivity; use broad-spectrum sunscreen during regular use
Frequently Asked Questions
What is doxy-PEP and how do I get it prescribed? Doxy-PEP is a single 200 mg dose of doxycycline taken within 72 hours after unprotected sex to reduce the risk of chlamydia, syphilis, and gonorrhea. You can obtain a prescription through a licensed telehealth provider or a sexual health clinic after a brief consultation covering your sexual health history and recent STI test results. Prescriptions go to any local pharmacy, and the medication is inexpensive.
Does doxy-PEP prevent HIV? No. Doxycycline has no activity against HIV. Doxy-PEP targets bacterial STIs only. If you are at risk for HIV, talk with your provider about PrEP (pre-exposure prophylaxis), which is a separate, highly effective prevention strategy.
How soon after sex does doxy-PEP need to be taken? Within 72 hours — three days. Earlier is better. Research suggests that earlier administration produces higher tissue concentrations and better outcomes, though the full 72-hour window remains within the recommended protocol.
Is doxy-PEP available for women? The CDC currently makes no recommendation for or against doxy-PEP in cisgender women due to insufficient clinical trial data in this population. Some sexual health providers discuss it on a case-by-case basis for individuals at very high ongoing STI risk. If you are interested and cisgender female, ask your provider whether the current evidence supports considering it for your specific situation.
Will using doxy-PEP make gonorrhea harder to treat if I get it? Real-world data from 2026 show doxy-PEP no longer meaningfully protects against gonorrhea in many regions due to rising tetracycline resistance in N. gonorrhoeae. The broader concern is whether widespread use accelerates this resistance at the population level. Gonorrhea infections are still treatable with ceftriaxone, which is unrelated to doxycycline, but your provider can help you weigh individual benefit against this evolving public health consideration.
Doxy-PEP is one of the more nuanced tools in sexual health prevention — genuinely effective against chlamydia and syphilis, but increasingly limited against gonorrhea and requiring regular monitoring. If you’re an MSM or transgender woman with a recent bacterial STI and want to discuss whether doxy-PEP belongs in your prevention plan, Omnia TeleHealth’s licensed providers are available for confidential, judgment-free consultations. Visit our STI/STD Testing & Treatment page to schedule an appointment and get the conversation started.